Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

Immunic (NASDAQ:IMUX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to ...

WHEN life gave Lina Nielsen lemons, she sprinted straight to the Olympics.  The 28-year-old was diagnosed with multiple sclerosis at 17 years old, leaving her terrified of disability. Doctors gave ...

Bleakley Financial Group LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund purchased 8,140 shares of the ...

In a challenging market environment, Immunic, Inc. (NASDAQ:IMUX) stock has recorded a new 52-week low, dipping to $0.92. The biopharmaceutical company, which focuses on developing treatments for ...

Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with MS in those ...

Adults with relapsing MS rated the Sensoready pen, an autoinjector used to self-administer Kesimpta, for ease of use and ...

Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the onset of MS symptoms. Women with multiple sclerosis (MS) show increased risk ...